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Chemical mutagenicity is a major hazard that is important to workers’ health. Despite the use of large
amounts of allyl chloride, the available mutagenicity data for this chemical remains controversial. To
clarify the mutagenicity of allyl chloride and because a micronucleus (MN) test had not yet been con-
ducted, we screened for MN induction by using male ICR mice bone marrow cells. The test results
indicated that this chemical is not mutagenic under the test conditions. In this paper, the regulatory test
battery and several assay combinations used to determine the genotoxic potential of chemicals in the
workplace have been described. Further application of these assays may prove useful in future devel-
opment strategies of hazard evaluations of industrial chemicals. This study also should help to improve
the testing of this chemical by commonly used mutagenicity testing methods and investigations on the
underlying mechanisms and could be applicable for workers’ health.
Copyright  2015, Occupational Safety and Health Research Institute. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chemicals may have various hazardous effects on human health
or the environment, and chemical hazard evaluations are impor-
tant for workers’ health and work environments. Depending on
toxicity, classiﬁed substances and their mixtures may require
restricted exposure in workplaces. There is an increased need for
chemical hazard assessments because the number of workers that
are exposed to chemicals has risen with the development of many
industries, and it is necessary to determine what these substances
are and how they are regulated [1].
One chemical, allyl chloride (CAS number 107-05-1), is used in
many industries, which has led to concerns about possible threats
to the health of workers. Only insufﬁcient or controversial infor-
mation is available concerning the potential related hazards of allyl
chloride; therefore, an in vivo micronucleus (MN) assay was con-
ducted to gain additional information concerning any such hazards.
Furthermore, toxicological information [e.g. the Safety Data Sheetth Center, Occupational Safety and
a.
upational Safety and Health Resear
by-nc-nd/4.0/).(SDS)] from this study could be applied for workers’ rights in
several industries.
Allyl chloride is used in the synthesis of allyl compounds [2]; as
an intermediate for the manufacture of polymers, resins, plastics
[3]; for varnishes and adhesives; and in the synthesis of pharma-
ceuticals and insecticides [4]. In the United States, this chemical is
listed as a high production volume (HPV) chemical (65FR81686),
which means that >1 million pounds was produced or imported
into the United States in 1990 and/or in 1994 [5]. In workplaces
where allyl chloride is produced or used, occupational exposure to
allyl chloride may occur through inhalation and dermal contact [6].
Allyl chloride has already been tested for mutagenicity by the
following short-term tests: Salmonella reversion test with strains
TA1535 and TA100 (with and without activation), a forward and
back mutation system in Streptomyces coelicolor, and two forward
mutation systems in Aspergillus nidulans. Spot and plate incorpo-
ration assay techniques are also employed. Allyl chloride was active
in Salmonella typhimurium and Salmonella coelicolor and negative inHealth Research Institute, Korea Occupational Safety and Health Agency, Number
ch Institute. Published by Elsevier Ltd. This is an open access article under the CC BY-
Table 1
Physicochemical and toxicological information of allyl chloride*
Chemical name Allyl chloride
CAS No. 107-05-1
Synonyms 1-Chloro-2-propene
1-Propene, 3-chloro-
2-Propenyl chloride
3-Chloropropene
Chlorallylene
p-Aminopropiofenon
1-Chloropropylene
Molecular formula C3H5Cl
Molecular weight 76.5
Melting point 135C
Forms Colorless liquid
Partition coefﬁcient 2.1
Boiling point 45C
Water solubility 0.337 g/100 mL at 25C
Stability & reactivity Chemical stability: stable under recommended
storage conditions
Conditions to avoid: heat, ﬂames, & sparks;
temperature extremes; & direct sunlight
Materials to avoid: oxidizing agents, boron
triﬂuoride, sulfuric acid, nitric acid, & strong
oxidizing agents
Toxicity Target organs: liver, respiratory system
Human LCLo inhalation, 3000 ppm
Mouse LC50 inhalation, 11500 mg/m3/2H
Mouse LD50 intraperitoneal, 155 mg/kg
Mouse LD50 oral, 425 mg/kg
Rabbit LCLo inhalation, 22500 mg/m3/2 h
Rabbit LD50 skin, 2066 mg/kg
Rat LC50 inhalation, 11 gm/m3/2H
Rat LD50 oral, 460 mg/kg
Guinea pig LC50 inhalation, 5800 mg/m3/2 h
Allyl chloride is classiﬁed as Group 3 (i.e., not
classiﬁable regarding its carcinogenicity to humans)
in IARC, A3 in ACGIH, & Carc 2 in EU-CLP
GHS classiﬁcation Flammable liquids (Category 2)
Acute toxicity, oral (Category 4)
Acute toxicity, inhalation (Category 3)
Skin irritation (Category 2)
Eye irritation (Category 2)
Carcinogenicity (Category 2) in MoEL of Korea &
the IARC Group 3
Germ cell mutagenicity (Category 2) in the MoEL
of Korea
Speciﬁc target organ toxicity-single exposure
(Category 3), respiratory system
ACGIH, American Conference of Governmental Industrial Hygienists; CAS, Chemical
Abstract Service; EU-CLP, European Union Classiﬁcation, Labelling, and Packaging;
GHS, Globally Harmonized System of Classiﬁcation and Labeling of Chemicals; IARC,
International Agency for Research on Cancer; LC50, median lethal concentration;
LCLo, lowest lethal concentration; MoEL, Ministry of Employment and Labor.
* The information is mostly obtained from searching ChemIDplus Advanced, U.S.
National Library of Medicine (Rockville Pike, Bethesda, MD; http://chem.sis.nlm.nih.
gov/chemidplus/rn/107-05-1), and Material Safety Data Sheet in KOSHANET (Ulsan,
Korea; http://msds.kosha.or.kr/kcic/msdsdetail.do). The searches were conducted
using keywords, the chemical name, and/or the CAS number.
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induce chromosomal aberrations in Chinese hamster lung (CHL/IU)
cells; we therefore proceeded to perform an in vivo MN assay. This
was necessary to improve the evaluation of the carcinogenic po-
tential of this compound.
The purpose of the MN test is to screen for cytogenetic damage
that results in the formation of micronuclei containing lagging
chromosome fragments or whole chromosomes. Micronuclei were
ﬁrst used to quantify chromosomal damage and are now recog-
nized as one of themost successful and reliable assays for genotoxic
carcinogens [9].
In the in vivoMN test, mammalian bonemarrowcells are treated
with allyl chloride. Many toxicological studies other than the MN
test have been conducted, although the available genotoxic data on
allyl chloride remain controversial with and without mammalian
metabolic activation (S9). Therefore, to secure quality assurance,
further study was necessary that was based on good laboratory
practice (GLP) guidelines.
Table 1 shows physicochemical and toxicological information
regarding allyl chloride. Using the Globally Harmonized System of
Classiﬁcation and Labeling of Chemicals (GHS) classiﬁcation, a
“mutagen” is an agent that increases the occurrence of mutations in
populations of cells and/or organisms. Substances and mixtures in
this hazard class are assigned to one of two hazard categories.
Category 1 has two subcategories (Table 2). Many studies have
focused on themutagenicity of allyl chloride (Table 3; however, with
the exception of our previous study [8], no study has used GLP tests.
Allyl chloride is nevertheless has category 2 germ cell mutagen
notiﬁed classiﬁcation and labeling, according to Classiﬁcation,
Labelling, and Packaging (CLP) criteria [10] on the evidence of these
non-GLP dataset. The CLP regulation ensures that the hazards pre-
sented by chemicals are clearly communicated to workers and con-
sumers in the European Union (EU) through the classiﬁcation and
labeling of chemicals. A public notice of theMinistry of Employment
and Labor (MoEL) of Korea (Sejong, Korea) [11] has also classiﬁed it as
a Category 2 germ cell mutagen following European Union Classiﬁ-
cation, Labelling, and Packaging classiﬁcation (EU-CLP).
Therefore, the MN assay accorded by GLP guidelines [12] was
necessary to determine its mutagenicity exactly and propose it to a
regulatory body such as the MoEL of Korea.
2. Materials and methods
2.1. Chemicals, animals, and experimental design
The test compound used in the in vivoMN test was allyl chloride
(98.5%; Sigma-Aldrich, St. Louis, MO, USA; lot numberMKBP7862V;
cat. number 236306). Olive oil (Sigma-Aldrich; lot number
BCBM3643V; cat. number O1514) was used as a solvent in accor-
dancewith the results of the solubility test. The positive control was
mitomycin C (MMC; Sigma-Aldrich; lot number SLBF9516V,Cat. No.
M4287).
The mouse (Mus musculus) bone marrow MN test was per-
formed in accordance with the Organisation for Economic Co-
operation and Development (OECD) Test TG 474 guidelines [12],
and in accordance with Hayashi [13] and Heddle et al [14]. Groups
of speciﬁc pathogen-free male ICR mice were treated with the test
substance at three dosage levels. The highest dosage level was the
estimated maximum tolerated dose or the standard limit dose for
the MN test, whichever was lower. Concurrent negative group (i.e.,
olive oil) and positive control group (MMC, 0.5 mg/kg) were also
treated. This study used 7-week old male ICR mice that were
administered allyl chloride at 100 mg/kg, 200 mg/kg, and 400 mg/
kg doses. At 24 hours post-treatment, six male animals that had
been administered allyl chloride orally were used for each group.The Animal Ethics Committee of OSHRI, KOSHA approved the ani-
mal studies protocol (approval number IACUC-1403) to ensure
appropriate care before the animals were obtained for research.
2.2. Bone marrow preparation and MN test
Twenty-four hours after the administration of allyl chloride the
animals were euthanized and bone marrow cells were harvested
from the mice femurs because of the cell cyle. Immature erythro-
cytes could be differentiated by using a variety of staining
Table 2
Germ cell mutagenicity classiﬁcation and standard assays in GHS classiﬁcation
Category 1. Known/presumed
Known to produce heritable mutations in human germ cells
Subcategory 1A
Positive evidence from epidemiological studies
Subcategory 1B
Positive results in:
, In vivo heritable germ cell tests in mammals
, Human germ cell tests
, In vivo somatic mutagenicity tests, combined
with some evidence of germ cell mutagenicity
Category 2. Suspected/possible
,May include heritable mutations in human germ cells
,Positive evidence from tests in mammals & somatic cell tests
, In vivo somatic genotoxicity supported by in vitro mutagenicity
GHS, Globally Harmonized System of Classiﬁcation and Labeling of Chemicals.
Note. From: A Guide to The Globally Harmonized System of Classiﬁcation and La-
beling of Chemicals (GHS) [Internet]. Washington (DC):Occupational Safety and
Health Administration (OSHA). 2003 [cited 2015 Jun 18]. Available from: https://
www.osha.gov/dsg/hazcom/ghs.html#3.2. Copyright 2013, Occupational Safety
and Health Administration (OSHA), Reprinted by permission.
Saf Health Work 2015;6:184e191186techniques that rely on the relatively high content of the cells’ re-
sidual DNA. Mature erythrocytes with a low nucleic acid content
appear pink to orange when stained with 5% Giemsa, whereas
immature erythrocytes stain blue. Based on the cell cycle and
maturation times of the erythrocytes, the bone marrow was har-
vested after 24 hours.
The bone marrow was ﬂushed from the femurs and spread onto
slides. The slideswere air-dried, ﬁxed, and stainedwith a ﬂuorescent
DNA-speciﬁc stain that easily illuminates any micronuclei that may
be present. To evaluate the cytotoxicity, the preliminary tests were
performed as a limit test to determine the maximum dosage. The
inhibition of proliferation in the bonemarrowcells was not observed
in this test. To indicate chemically induced toxicity, the percentage of
polychromatic erythrocytes (PCEs) among the 500 erythrocytes in
the bone marrow was recorded for each dosage group.Table 3
Summary of studies focusing on in vitro and in vivo mutagenicity and carcinogenicity of
Tests Species Protocol
Genetic toxicity in vitro
bacteria test
(gene mutation)
Salmonella typhimurium Plate inc. assay
Spot test
Liquid susp. assay
Escherichia coli Spot test
Nonbacterial in vitro
test (gene mutation)
Streptomyces coelicolor Plate inc. assay
Spot test
Aspergillus nidulans
Saccharomyces
cerevisiae
Plate inc. assay
Spot test
Liquid suspension assay
Nonbacterial in vitro test
(chromosomal aberration)
A. nidulans
Rat liver RL1
Other
Other
Human HeLa S3 H3-thymidine incorp.
DNA-modifying activity E. coli Other
Genetic toxicity in vivo Rat/CD
Rat/DC
Micronucleus test Domi
lethal assay
Sperm abnormality
Mouse/B6C3F1 SLRL test
Drosophila melanogaster
SLRL, sex-linked recessive lethal; UDS, unscheduled DNA synthesis.
* Information is mostly obtained by searching in United Nations Environment Program
UNEP Publications; 1996.At least 2,000 polychromatic erythrocytes (PCEs; e.g., re-
ticulocytes, immature erythrocytes) were scored per animal with
regard to the frequency of micronucleated cells in each of the six
animals per dosage group. The presence of micronucleated PCEs
was visually scored (at least 2,000 cells per mouse) by optical mi-
croscopy using a ﬂuorescence microscope (Opti phot-2; Nikon,
Tokyo, Japan) with a BA-2 ﬁlter. Cells were considered micro-
nucleated if they neatly contained deﬁned chromatin corpuscles
with a diameter less than one-third the diameter of the cell nu-
cleus, and if they stained an equal or lighter shade than the nucleus
of the cell from which the micronucleated cell was developed. To
reduce observer bias, only one reader was involved in scoring cells.
2.3. Evaluation and interpretation of the results
According to OECD TG 474 Test (i.e., Mammalian Erythrocyte
Micronucleus Test) [12], the evaluation and interpretation of results
were based on data that were presented as the mean number of
micronucleated cells per 2,000 cells for each treatment group. The
experimental and control MN frequency for each specimen within
and between different mice strains were compared with a one-way
analysis of variance test using SigmaStat version 3.11 software
(Systat Software, Inc., San Jose, CA, USA). There is no requirement
for veriﬁcation of a clear positive or clear negative response.
2.4. Journal and book review
With particular emphasis on three topicsdchemical mutage-
nicity, mutagenic tests associated with industrial chemicals, and
the prevention of occupational diseasesdwe would like to discuss
the prospects for developing a strategy for applying novel muta-
genicity assays that are applicable for workers’ health issues such as
occupational cancer.
Searches were performed on the following sites: PubMed
(http://www.ncbi.nlm.nih.gov/pubmed), Google Scholar (http://
scholar.google.com), and ScienceDirect (www.sciencedirect.com).allyl chloride*
Results Refs
2 tests negative, 1 positive in TA1535 with S9 Dean et al [40]
McCoy et al [41]
2 tests positive (in TA1535 with S9)
(in TA1535 with & without S9)
Neudecker &
Henschler [42]
Positive in TA100 without S9 Eder et al [43]
Positive with & without S9
Positive for both forward & reverse mutation Bignami et al [7]
Positive for both forward & reverse mutation
Negative
Negative
Positive both with & without S9
Increase in haploid segregants & diploid
nondisjunctional sectors
negative
Crebelli et al [44]
Dean et al [40]
Positive UDS Schiffmann et al [45]
Positive in pol A1 McCoy et al [41]
nant Negative
Negative
McGregor [46]
Negative
Negative
me (UNEP). OECD SIDS report: chloropropene (CAS no.: 107-05-1). Nairobi (Kenya):
Table 4
Animal body weight in micronucleus tests after oral exposure to allyl chloride
Exposure method Concentration No. of
animals
Average body
weight
(g; mean  SD)
Orally exposed to allyl
chloride for 24 h
Negative control
(olive oil)
6 37.97  1.59
100 mg/kg b.w. 6 37.98  1.86
200 mg/kg b.w. 6 38.08  1.53
400 mg/kg b.w. 6 37.89  1.55
Positive control
(MMC, 0.5 mg/kg b.w.)
6 37.68  1.86
b.w., body weight; MMC, mitomycin C.
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Subject Headings (MeSH; National Center for Biotechnology Infor-
mation, Bethesda, MD) terms and keywords: “allyl chloride” and
“mutagenicity test” or “workers” or “occupations.” The search re-
sults were further narrowed by reviewing titles and abstracts by
two reviewers (the authors). Inclusion criteria were epidemiology,
in vitro and in vivo mutagenicity and carcinogenicity studies.
Additional missing case reports were identiﬁed by reviewing the
references of review articles and bibliographies found on scholar.
google.com. Disagreements in article and conference abstract
identiﬁcation were resolved by mutual discussion. Based on the
literature review results, our search strategy identiﬁed 632 po-
tential articles (Fig. 1). The reviewers agreed on 31 articles (i.e.,
references [13,14,16e33,36e46]) and three books (i.e. [15,34,35])
that met the inclusion criteria for detailed analysis.
3. Results and discussion
There were no speciﬁc symptoms among the animals that were
orally exposed to allyl chloride. The body weight of the animals
exposed to this chemical ranged 35.74e40.20 g (Table 4). There
were no environmental factors that may have affected the quality
or integrity of the study results, which includes any signiﬁcant
behavioral changes (i.e., neurophysiological activity).
Preliminary tests were performed to determine the maximum
dosage. The proliferation of bone marrow cells was not inhibited in
this test. The presence of micronucleated PCEs was visually scored
by optical microscopy using a ﬂuorescence microscope (Fig. 2).
The frequency of erythrocytes with MN inductions was
0.19  0.05% in the negative control group; 0.27  0.18%,
0.30  0.10%, and 0.38  0.10% in the 100 mg/kg, 200 mg/kg, and
400 mg/kg allyl chloride-treated groups, respectively; and
1.19  0.22% in the positive control group. The ratio of PCEs within
the total number of erythrocytes was 63.03  3.21% in the negative
control group; 46.10  5.60%, 53.89  5.98%, and 46.74  4.23% in
the 100 mg/kg, 200 mg/kg, and 400 mg/kg allyl chloride-treated
groups, respectively; and 45.07  9.03% in the positive control
group. There were no statistically signiﬁcant changes in compari-
son to the negative control group (Table 5).
In this study, we performed in vivoMN tests based on the results
of a dose range-ﬁnding assay. The maximum dose was estimated at
400 mg/kg, based on regulatory guidelines. Bone marrow was
extracted, and at least 2,000 PCEs per animal were analyzed for theFig. 1. Flow diagram of afrequency of micronuclei. Cytotoxicity was assessed by scoring the
number of PCEs and normochromatic erythrocytes (NCEs) in at
least the ﬁrst 500 erythrocytes for each animal. Allyl chloride did
not induce signs of clinical toxicity in the animals treated at the
highest dose level (based on regulatory guidelines). The chemical
also did not induce statistically signiﬁcant increases in micro-
nucleated PCEs at any dose. It was also not cytotoxic to the bone
marrow (i.e., it did not produce statistically signiﬁcant decreases in
the PCE:NCE ratio) at any dose.
When a bonemarrowerythroblast develops into a PCE, themain
nucleus is extruded. Any MN that has been formed may remain
behind in an otherwise anucleated cytoplasm. Visualization of the
micronuclei is facilitated in these cells because they lack a main
nucleus. An increase in the frequency of MNPCEs in treated animals
is an indication of induced chromosomal damage. Statistical sig-
niﬁcance should not be the only determining factor for a positive
response: positive results in a MN test indicate that a substance
inducesmicronuclei because of chromosomal damage or damage to
the mitotic apparatus in the erythroblasts of the test species. We
evaluated and interpreted these results according to OECD guide-
lines [12]. The experimental and control MN frequency for each
specimen within and between different mice strains were
compared. There was no requirement for veriﬁcation of a clear
positive or clear negative response.
Table 6 shows the in vitro and in vivo genetic toxicity assays that
optimize the standard battery for genetic toxicology recommended
by the International Conference on Harmonisation (ICH; Geneva,
Switzerland) [15]. Allyl chloride was tested for mutagenicity in article identiﬁcation.
Fig. 2. The presence of micronucleated polychromatic erythrocytes. Micronucleated
mouse bone marrow cells with Giemsa staining under optical microscopy. The arrow
shows a true micronucleus (magniﬁcation, 1,000).
Table 6
In vitro and in vivo genetic toxicity assays that optimize the standard battery for
genetic toxicology recommended by the International Conference on Harmonisation
Test name * No./Chapter No.
OECD EPA-OCSP FDA Redbook
2000
In vitro Bacterial reverse
mutation test (Ames test)
471 870.5100 IV.C.1.a.
In vitro mammalian
chromosome aberration
assay
473 870.5375 IV.C.1.b.
In vitro mammalian cell
micronucleus test
487 None None
In vitro mammalian cell
gene mutation test
476 870.5300 IV.C.1.c.
(only MLA)
In vivo Mammalian micronucleus
test
474 870.5395 IV.C.1.d.
(only
erythrocyte)
Mammalian bone marrow
chromosome aberration
test
475 870.5385 None
Unscheduled DNA synthesis
(UDS) test with mammalian
liver cells in vivo
486 None None
Transgenic mouse mutation
assay
488 None None
In vivo comet assay None None None
Alkaline elution assay None None None
In vivo DNA covalent binding
assay
None None None
EPA, Environmental Protection Agency; FDA, Food and Drug Administration; MLA,
methyllycaconitine; OCSP, the Ofﬁce of Chemical Safety and Pollution Prevention;
OECD, Organisation for Economic Co-operation and Development.
Note. From R.D. Harbison, M.M. Bourgeois, and G.T. Johnson, Hamilton and Hardy’s
Industrial Toxicology, 6th ed, p. 1183. Copyright 2015, Hoboken (NJ): John Wiley &
Sons, Inc. Adapted with permission.
* The recommended International Conference on Harmonisation standard test
battery.
Saf Health Work 2015;6:184e191188battery of in vitro and in vivo assays. In the older in vitro assays
negative results were obtained, possibly because of the vapor-
ization of allyl chloride. Adequate mutagenicity assays with S.
typhimurium were positive with and without metabolic activation.
The mutagenicity greatly decreased in the presence of an exoge-
nous activating system. In a spot test with Escherichia coli and in
tests with Streptomyces coelicolor positive results were obtained
with and without metabolic activation. Tests with A. nidulans were
negative for allyl chloride. The substance induces gene conversions
in Saccharomyces cerevisiae and somatic segregation in A. nidulans.
No signiﬁcant compound-related chromosome damage was
observed in RL1 cells. Allyl chloride induces unscheduled DNA
synthesis in human HeLa S3 cells, but not in human embryonic
intestinal cells. No increase in chromosomal aberrations was
observed in a cytogenetic test with rats exposed to allyl chloride by
inhalation. The substance was negative in a dominant lethal assay
with rats and in a sperm abnormality test with mice. Allyl chloride
did not increase sex-linked recessive lethal mutations in Drosophila
melanogaster. Based on all available mutagenicity data, it can be
concluded that allyl chloride is mutagenic to bacteria and yeast and
it induces unscheduled DNA synthesis in human HeLa cells but not
in embryonic testinal cells. Allyl chloride did not cause chromo-
some aberrations in vitro in mammalian cells. Negative results were
obtained in the available in vivo tests (Table 3).
A stepwise tiered approach is applied in regulatory mutage-
nicity testing [16]. In the ﬁrst step, in vitro assays with a high
sensitivity are used to identify test compounds that have high
intrinsic genotoxic activity. In the second step, speciﬁc in vivo tests
are performed to determine the relevance of the in vitro results for
the in vivo situation. These in vivo mutagenicity studies are also
included because some genotoxicants can only be detected in vivo
after metabolic activation [17]. Compared to regulatoryTable 5
Results of the main micronucleus test with allyl chloride (for 24 hours)
Groups PCE observed MNPCE observed MNPCE fre
Negative control 2,033.83  19.05 3.83  0.98 0.19  0.05
100 mg/kg b.w. 2,045.50  63.98 5.50  3.56 0.27  0.18
200 mg/kg b.w. 2,048.33  40.90 6.17  1.94 0.30  0.10
400 mg/kg b.w. 2,023.33  13.02 7.67  2.07 0.38  0.10
Positive control
(MMC, 0.5 mg/kg b.w.)
2,027.00  15.84 24.17  4.45 1.19  0.22
Dats are presented as mean  the standard deviation.
b.w., body weight; MMC, mitomycin C; MNPCE, micronucleated polychromatic erythroccarcinogenicity testing, mutagenicity testing is relatively cheap and
fast. Compounds without genotoxic liability can proceed ﬁrst into
clinical trials in humans. The carcinogenic potential is assessed later
in the full developmental phase of drug development; however, the
regulatory test strategy consists of a battery of core and ancillary
tests for identifying the three forms of mutagenicity (i.e., gene
mutations, clastogenicity, and aneugenicity), which cannot be
detected in one single test.
Genotoxicity tests are used to detect genetic damage by various
mechanisms in in vitro and in vivo systems. Several regulatory
guidelines have been developed to provide various assays that are
conducted for testing the genotoxicity. To date, most regulatory
agencies and international authorities recommend a test scheme
consisting of in vitro and in vivo methods to detect genotoxicity/
mutagenicity induced by substances. The ICH recommends a
standard battery test for pharmaceuticals to detect theirquency (%) PCE þ NCE counted PCE counted PCE/(PCE þ NCE) (%)
516.83  13.11 325.83  20.07 63.03  3.21
520.00  15.49 240.33  36.13 46.10  5.60
510.17  5.81 275.17  33.11 53.89  5.98
512.83  14.72 239.50  19.69 46.74  4.23
517.50  28.48 234.83  59.44 45.07  9.03
yte; NCE, normochromatic erythrocyte; PCE, polychromatic erythrocyte.
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for genetic toxicology and provides guidelines on the interpretation
of results (Table 6) [15]. These guidelines help improve risk char-
acterization for carcinogenic effects. In the following sections, some
regulatory agencies or organizations are brieﬂy described with
regard to their own guidelines.
The Ames assay has a relatively high speciﬁcity, compared to
other in vitro mutagenicity tests (Table 7). The sensitivity, speci-
ﬁcity, and predictivity of the Ames assay calculated by Kirkland et al
[18] were 58.8%, 73.9%, and 62.5%, respectively.
The chromosome aberration test is performed in vitro in
cultured mammalian cells. It is also performed in the presence and
in the absence of the S9 mixture [19,20]. Scoring the test requires
specialized training and experience. The sensitivity and predictivity
of carcinogenicity for this test are 65.6% and 59.8%, respectively. The
speciﬁcity of this test is low (44.9%).
The sensitivity and predictivity of the mouse lymphoma
thymidine kinase assay is 73.1% and 62.9%, respectively. As for the
chromosome aberration assay, the speciﬁcity of this assay is low
(39%).
The fourth regulatory mutagenicity assay is the MN test. The
sensitivity, speciﬁcity, and predictivity of the in vitro MN assay are
78.7%, 30.8%, and 67.8%, respectively. The speciﬁcity of the in vivo
MN assay in bone marrow is much higher (75%). The sensitivity of
the in vivo test is lower (40%) and the predictivity is 48% [21,22].
In this paper, a regulatory test battery to determine the geno-
toxic potential of industrial chemicals has been described. The
validation data for these higher throughput assays show that bac-
terial mutagenicity (i.e., gene mutations) and mammalian muta-
genicity (i.e., chromosome damage) can be predicted early. To
develop a strategy for applying the novel mutagenicity assays in the
lead optimization phase, several combinations of assays must be
evaluated. Further application of these assays may prove useful in
future development strategies of chemicals.
The toxicological relevance of the MN test is well deﬁned: it is a
multitarget genotoxic endpoint; it assesses clastogenic and aneu-
genic events; and it assesses some epigenetic effects, which is
simple to score, accurate, and applicable in different cell types. In
addition, it is predictive for cancer, amenable for automation, and
allows good extrapolation for potential limits of exposure or
thresholds. It is easily measured in experimental in vitro and in vivo
systems. Implementation of in vitromicronucleus (IVMN) assays in
the battery of tests for hazard and risk assessment of potential
mutagens/carcinogens is therefore fully justiﬁed. The ﬁnal draft of
the OECD guideline is available for this test [20].
The presence of MN in cultured human cells was reported as
early as the 1960s [21] and 1970s [22]. The in vitro micronucleus
test (IVMNT) has evolved into a robust quantitative assay of chro-
mosome damage by the development of the cytokinesis-block
technique that eliminated the confounding effects on MNTable 7
The sensitivity, speciﬁcity, and predictivity of the assays of the standard regulatory
test battery for the assessment of carcinogenicity [18,19]
Assay Sensitivity (%) Speciﬁcity (%) Predictivity (%)
Ames test 58.8 73.9 62.5
Chromosome aberration test 65.6 44.9 59.8
Mouse lymphoma TK test 73.1 39.0 62.9
Micronucleus test in vitro 78.7 30.8 67.8
Micronucleus test in vivo 40.0 75.0 48.0
TK, thymidine kinase.
Note. From P. Steinberg (editor), High-throughput Screening Methods in Toxicity
Testing, p. 213e69, Copyright 2013, Hoboken (NJ): John Wiley & Sons, Inc., Adapted
with permission.expression by the cytostatic effects caused by poor culture condi-
tions, treatment effects, cell senescence, and variability in mitogen
response in the lymphocyte test system [23].
In the cytokinesis-blockmicronucleus (CBMN) assay, the scoring
of MN discriminates between the accumulation of once-divided
cells that appear binucleated and mononucleated cells that did
not divide during the in vitro culturing period [24]. In recent years,
the IVMNT has become an attractive tool for mutagenicity testing
because of its capacity to detect clastogenic and aneugenic events
and some epigenetic effects and because of the simplicity of
scoring; its accuracy, wide applicability in different cell types; and
its amenability to automation. More recently, the ﬁnal draft of the
OECD guideline 478 has become available [24]. The initial recom-
mendations for this guideline came from two workshops [by the
International Workshops on Genotoxicity Testing (IWGT)], which
proposed an internationally harmonized protocol designed for
human primary lymphocytes and for cell lines [25,26]. The Euro-
pean Centre for the Validation of Alternative Methods (ECVAM)
validated the methodology by retrospectively examining the
existing published data on the IVMNT [27e31] using the modular
approach for validation [32]. The ECVAM conﬁrmed that the IVMNT
is reliable, reproducible, transferable, and predictive [33], and
ECVAM Scientiﬁc Advisory Committee endorsed the IVMNT
[34,35]. The ﬁnal step before acceptance by the OECD consists of an
interlaboratory exercise to evaluate different measures of cytotox-
icity/cytostasis that can be applied when the IVMNT is performed in
the absence of cytochalasin B [34]. The use of the IVMNT within a
battery of tests will be deﬁned by various regulatory bodies
responsible for developing such test strategies. The advantages of
the IVMNT are well deﬁned and discussed by Bonassi et al [36],
Decordier et al [37], and Elhajouji et al [38]: it is a multitarget
genotoxic endpoint and predictive for cancer [39], it is amenable for
automation [38], and it allows good extrapolation for potential
limits of exposure or thresholds [38]. In addition, the MN can be
scored and easily measured in a variety of in vitro and in vivo sys-
tems [39]. Implementation of IVMN assays in the battery of tests for
hazard and risk assessment of potential mutagens/carcinogens is
therefore fully justiﬁed.
Many ﬁndings have been used to determine the mutagenicity of
allyl chloride; however, no GLP tests have been performed, except
for our previous study [8]. It is nevertheless classiﬁed as a Category
2 germ cell notiﬁed mutagen and labeled according to CLP criteria
on the evidence of these non-GLP dataset. A Public Notice of min-
istry of employment and labor (MoEL), Korea was also classiﬁed it
as a category 2 germ cell mutagen in accordance wtih the classiﬁ-
cation of the European Union Classiﬁcation, Labelling, and Pack-
aging (EU-CLP). Therefore, the MN assay accorded by GLP
guidelines [12] was needed to determine exactly its mutagenicity
and propose it to a regulatory body such as the MoEL of Korea.
Based on these results and discussion, allyl chloride did not induce
micronuclei, as reﬂected by the MN test of the bonemarrow cells of
mice. Allyl chloride should be categorized as “not classiﬁed” as to its
mutagenicity, according to GHS.
Nevertheless, it is anticipated that allyl chloride will trigger
health problems of workers as occupational diseases. To predict
risks for workers’ health, especially occupational cancers, and to
improve the assessment of hazardous effects, we recommend
additional studies that focus on lung exposure and the long-term
effects of these low-level contaminants with inhalation. Allyl
chloride is practically regulated by Occupational Safety and Health
Act (OSHAct) in the MoEL of Korea with its carcinogenicity (Cate-
gory 2; Table 1).
Despite the use of large amounts of allyl chloride, the available
data for the mutagenicity of this chemical remains controversial.
We believe this is the ﬁrst study to involve an in vivoMN assay with
Saf Health Work 2015;6:184e191190a mouse bone marrow cells. In conclusion, the test substance allyl
chloride did not show any evidence of inducing MN under the
conditions of this study.
In this paper, a regulatory test battery has been described with a
medium or high throughput to determine the genotoxic potential
of chemicals at work. The validation data for these higher
throughput assays show that an early prediction is possible for
bacterial mutagenicity (i.e., gene mutations) and mammalian
mutagenicity (i.e., chromosomal damage). Several combinations of
assays must be evaluated to develop a strategy to apply the novel
mutagenicity assays in the lead optimization phase. Further appli-
cation of these assays may prove useful in future development
strategies of hazard evaluations of industrial chemicals.
Many ﬁndings have been used to determine the mutagenicity of
allyl chloride; however, no GLP tests have been performed, except
in our previous study [8]. Allyl chloride is nevertheless classiﬁed as
a Category 2 germ cell notiﬁed mutagen and labeled according to
EU-CLP criteria on the evidence of these non-GLP dataset. The
public notice of the MoEL of Korea also classiﬁed it as a category 2
germ cell mutagen in accordance with the classiﬁcation of the EU-
CLP. However, based on these results and discussion, the mutage-
nicity of allyl chloride should be “not classiﬁed” according to GHS.
This study was performed with GLP guidelines to determine
exactly its mutagenicity and propose it to a regulatory body such as
the MoEL of Korea. This study also should help to improve the
testing of this chemical by commonly used mutagenicity testing
methods and investigations on the underlying mechanisms and
could be applicable for workers’ health issues, which include
occupational cancers.Conﬂicts of interest
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